Hologic, Inc. $HOLX Shares Bought by USS Investment Management Ltd

Key Points

• USS Investment Management Ltd increased its stake in Hologic, Inc. by 8.8%, owning 58,012 shares worth approximately $3.58 million as of the most recent SEC filing.
• Wall Street analysts have raised their target prices for Hologic, with upgrades from firms such as Evercore ISI and Royal Bank Of Canada, suggesting a growing confidence in the company's performance and projected growth.
• Hologic reported a quarterly earnings per share of $1.08, exceeding analysts' expectations, with a revenue of $1.02 billion, indicating a year-over-year revenue growth of 1.2%.

USS Investment Management Ltd grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 8.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 58,012 shares of the medical equipment provider's stock after purchasing an additional 4,684 shares during the period. USS Investment Management Ltd's holdings in Hologic were worth $3,584,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Victory Capital Management Inc. boosted its position in shares of Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after buying an additional 1,692,177 shares in the last quarter. Nuance Investments LLC boosted its position in shares of Hologic by 623.7% in the 1st quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock worth $66,794,000 after buying an additional 931,920 shares in the last quarter. Redwood Wealth Management Group LLC purchased a new stake in shares of Hologic in the 1st quarter worth about $3,534,000. Invesco Ltd. boosted its position in shares of Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after buying an additional 764,573 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Hologic in the 1st quarter worth about $30,317,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and boosted their price objective for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Needham & Company LLC restated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Morgan Stanley upped their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Mizuho set a $75.00 price objective on shares of Hologic in a research note on Thursday, July 31st. Finally, UBS Group upped their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Trading Down 2.9%

HOLX traded down $1.93 on Friday, reaching $64.45. 1,005,460 shares of the company's stock were exchanged, compared to its average volume of 1,330,759. The company's 50 day moving average is $66.43 and its 200-day moving average is $62.64. The company has a market cap of $14.33 billion, a price-to-earnings ratio of 26.74, a PEG ratio of 2.34 and a beta of 0.57. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.